{"id":"mil62","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Hyperlipidemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MIL62 binds to the IL-6 receptor, blocking the interaction between IL-6 cytokine and its receptor on immune and other cells. This inhibition suppresses downstream inflammatory signaling pathways, reducing the production of pro-inflammatory mediators and modulating immune cell activation. The mechanism is designed to address inflammatory and autoimmune conditions driven by IL-6 overexpression.","oneSentence":"MIL62 is a monoclonal antibody targeting IL-6 receptor to inhibit interleukin-6 signaling and reduce inflammatory responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:21:19.766Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Other IL-6-driven inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT07405970","phase":"PHASE3","title":"A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2026-02","conditions":"Systemic Lupus Erythematosus","enrollment":316},{"nctId":"NCT05796206","phase":"PHASE2","title":"A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2023-05-26","conditions":"Systemic Lupus Erythematosus","enrollment":120},{"nctId":"NCT05398653","phase":"PHASE1, PHASE2","title":"A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy","status":"COMPLETED","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2022-02-24","conditions":"Primary Membranous Nephropathy","enrollment":94},{"nctId":"NCT05314010","phase":"PHASE3","title":"A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2022-08-18","conditions":"Neuromyelitis Optica Spectrum Disorder","enrollment":102},{"nctId":"NCT05862233","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2023-06-02","conditions":"Primary Membranous Nephropathy","enrollment":150},{"nctId":"NCT07044115","phase":"PHASE1, PHASE2","title":"Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2021-11-26","conditions":"Lupus Nephritis","enrollment":41},{"nctId":"NCT04103905","phase":"PHASE1","title":"A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas","status":"COMPLETED","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2017-02-10","conditions":"CD20-positive B Cell Non-Hodgkin Lymphoma","enrollment":27},{"nctId":"NCT04110301","phase":"PHASE1, PHASE2","title":"MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)","status":"RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2019-11-28","conditions":"Follicular Lymphoma and Marginal Zone Lymphoma","enrollment":53},{"nctId":"NCT05806099","phase":"PHASE1, PHASE2","title":"A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL","status":"RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2023-06-28","conditions":"Non-Hodgkin's Lymphoma","enrollment":132},{"nctId":"NCT04834024","phase":"PHASE3","title":"MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2021-06-02","conditions":"Follicular Lymphoma and Marginal Zone Lymphoma","enrollment":168},{"nctId":"NCT04304040","phase":"PHASE1, PHASE2","title":"A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma","status":"UNKNOWN","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2020-07-28","conditions":"B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MIL62","genericName":"MIL62","companyName":"Beijing Mabworks Biotech Co., Ltd.","companyId":"beijing-mabworks-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MIL62 is a monoclonal antibody targeting IL-6 receptor to inhibit interleukin-6 signaling and reduce inflammatory responses. Used for Rheumatoid arthritis, Other IL-6-driven inflammatory conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}